Screening for thyroid malignancy: the role of fine‐needle biopsy

Cytological examination of the aspirate of fine‐needle biopsy is becoming more widely accepted as a screening test for malignancy in thyroid nodules. However, it tends to be used in addition to, rather than instead of, more traditional methods. In this five‐year prospective evaluation we performed fine‐needle biopsy in 618 euthyroid patients with nodular thyroid enlargement, 86% of whom also underwent radionuclide scans and 55% of whom underwent ultrasound scans. In 19% of patients fine‐needle biopsy yielded insufficient material for diagnosis, and in 14% of patients normal follicular cells were found (which indicated that the clinical lesion was not sampled). To date, a histological diagnosis has been obtained in 258 (42%) patients, 44 of whom had malignancies. The results of the radionuclide and ultrasound scans did not alter the odds in favour of the detection of malignancy. The cytological diagnosis of malignancy was falsely‐positive in two patients and falsely‐negative in four patients (three cases of which probably were sampling errors). If, in addition to overtly‐malignant cells, atypical Hürthle cells and follicular neoplasms were considered to be potentially malignant, fine‐needle biopsy alone had a sensitivity of 87% and a specificity of 72%. This good accuracy would be reduced by sampling failures, but a policy of operating on all patients with potentially‐malignant cells, or on those in whom satisfactory aspirates could not be obtained, would yield high rates of the diagnosis of malignancy and would reduce the number of operations. Our data indicate that the most‐appropriate method of screening thyroid nodules for malignancy is fine‐needle biopsy without pertechnetate scanning or ultrasound examinations.